Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Tango Therapeutics, Inc.

Clinicaltrial registered27 Oct 2026

Tango Therapeutics, Inc.

27 Oct 2026: Trial registered · TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
27 Oct 2026
Title
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
Conditions
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07897734
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Tango Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.